These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 16412789)

  • 21. Preferential usage of T cell receptor (TCR) V beta by allogeneic T cells recognizing myeloid leukemia cells: implications for separating graft-versus-leukemia effect from graft-versus-host disease.
    Jiang YZ; Mavroudis DA; Dermime S; Molldrem J; Hensel NF; Barrett AJ
    Bone Marrow Transplant; 1997 May; 19(9):899-903. PubMed ID: 9156263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse.
    Wysoczanska B; Bogunia-Kubik K; Dlubek D; Jaskula E; Sok A; Drabczak-Skrzypek D; Sedzimirska M; Lange A
    Transplant Proc; 2007 Nov; 39(9):2898-901. PubMed ID: 18022011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distinct T cell populations distinguish chronic myeloid leukaemia cells from lymphocytes in the same individual: a model for separating GVHD from GVL reactions.
    Datta AR; Barrett AJ; Jiang YZ; Guimarães A; Mavroudis DA; van Rhee F; Gordon AA; Madrigal A
    Bone Marrow Transplant; 1994 Oct; 14(4):517-24. PubMed ID: 7858526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Testicular relapse of AML during chronic graft-versus-host disease induced by donor leukocyte infusion.
    Tringali S; Vasta S; Scimè R; Catania P; Cavallaro AM; Majolino I
    Haematologica; 1996; 81(4):339-42. PubMed ID: 8870379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulating graft-versus-host disease to enhance the graft-versus-leukemia effect.
    Alyea EP
    Best Pract Res Clin Haematol; 2008 Jun; 21(2):239-50. PubMed ID: 18503989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Temporal discordance between graft-versus-leukemia and graft-versus-host responses: a strategy for the separation of graft-versus-leukemia/graft-versus-host reactivity?
    Hari P; Logan B; Drobyski WR
    Biol Blood Marrow Transplant; 2004 Nov; 10(11):743-7. PubMed ID: 15505605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation].
    Lin Q; Dong M; Wang QM; Wen JY; Wu XY
    Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model.
    Lu YF; Gavrilescu LC; Betancur M; Lazarides K; Klingemann H; Van Etten RA
    Blood; 2012 Jan; 119(1):273-84. PubMed ID: 22072555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fatal graft-versus-host disease following HLA-mismatched donor lymphocyte infusion.
    Amrolia PJ; Rao K; Slater O; Ramsay A; Veys PA; Webb DK
    Bone Marrow Transplant; 2001 Sep; 28(6):623-5. PubMed ID: 11607779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Experimental and clinical approaches for optimization of the graft-versus-leukemia effect.
    Sprangers B; Van Wijmeersch B; Fevery S; Waer M; Billiau AD
    Nat Clin Pract Oncol; 2007 Jul; 4(7):404-14. PubMed ID: 17597705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Second transplant from the same donor without conditioning for bone marrow aplasia after non-myeloablative hematopoietic stem cell transplantation for chronic myeloid leukemia].
    Ishikawa I; Miyamura K; Yamada M; Sasaki O; Harigae H; Kameoka J; Meguro K; Sasaki T
    Rinsho Ketsueki; 2005 Dec; 46(12):1288-92. PubMed ID: 16447801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population.
    Levine JE; Barrett AJ; Zhang MJ; Arora M; Pulsipher MA; Bunin N; Fort J; Loberiza F; Porter D; Giralt S; Drobyski W; Wang D; Pavletic S; Ringden O; Horowitz MM; Collins R
    Bone Marrow Transplant; 2008 Aug; 42(3):201-5. PubMed ID: 18490913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Donor leukocyte infusions after unrelated donor hematopoietic stem cell transplantation.
    Loren AW; Porter DL
    Curr Opin Oncol; 2006 Mar; 18(2):107-14. PubMed ID: 16462177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation.
    Orti G; Lowdell M; Fielding A; Samuel E; Pang K; Kottaridis P; Morris E; Thomson K; Peggs K; Mackinnon S; Chakraverty R
    Transplantation; 2009 Dec; 88(11):1312-8. PubMed ID: 19996931
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In relapsed patients after lymphocyte depleted bone marrow transplantation the percentage of donor T lymphocytes correlates well with the outcome of donor leukocyte infusion.
    Schattenberg A; Schaap N; Van De Wiel-Van Kemenade E; Bär B; Preijers F; Van Der Maazen R; Roovers E; De Witte T
    Leuk Lymphoma; 1999 Jan; 32(3-4):317-25. PubMed ID: 10037029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unrelated donor leukocyte infusions to treat relapse after unrelated donor bone marrow transplantation.
    Leis J; Porter DL
    Leuk Lymphoma; 2002 Jan; 43(1):9-17. PubMed ID: 11908741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Donor leukocyte transfusion for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation].
    Murata R; Shiohara S; Nakao S
    Rinsho Ketsueki; 2000 Apr; 41(4):288-91. PubMed ID: 10846457
    [No Abstract]   [Full Text] [Related]  

  • 38. Acute severe form of lichenoid graft-versus-host disease after donor lymphocyte infusions.
    Ruiz-Genao DP; F-Peñas P; Daudén E; García-F-Villalta MJ; Fraga J; García-Diez A
    J Eur Acad Dermatol Venereol; 2006 May; 20(5):632-4. PubMed ID: 16684312
    [No Abstract]   [Full Text] [Related]  

  • 39. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
    Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
    Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation.
    Loren AW; Porter DL
    Bone Marrow Transplant; 2008 Mar; 41(5):483-93. PubMed ID: 18026156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.